GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » Net Interest Income

EQL Pharma AB (FRA:7JK) Net Interest Income : €-0.35 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is EQL Pharma AB Net Interest Income?

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors. EQL Pharma AB's net interest income for the three months ended in Mar. 2024 was €-0.21 Mil. Its net interest income for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.35 Mil.

EQL Pharma AB Net Interest Income Historical Data

The historical data trend for EQL Pharma AB's Net Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EQL Pharma AB Net Interest Income Chart

EQL Pharma AB Annual Data
Trend Dec14 Dec15 Dec16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.04 -0.11 -0.27 -0.21 -0.35

EQL Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 0.06 -0.06 -0.14 -0.21

EQL Pharma AB Net Interest Income Calculation

Net interest income is the total interest income minus total interest expense. It represents the difference between interest and dividends earned on interestbearing assets and interest paid to depositors and other creditors.

Net Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB Net Interest Income Related Terms

Thank you for viewing the detailed overview of EQL Pharma AB's Net Interest Income provided by GuruFocus.com. Please click on the following links to see related term pages.

EQL Pharma AB (FRA:7JK) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » EQL Pharma AB (FRA:7JK) » Definitions » Net Interest Income
Comparable Companies
OSTO:ENZY OSTO:ORX OSTO:CRNO B OSTO:ALZCUR OSTO:MOB OSTO:ERMA OSTO:VIVE XSAT:PMED XSAT:ODI XSAT:DICOT ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
EQL:Sweden
Address
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
Website
http://www.eqlpharma.com
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.

EQL Pharma AB (FRA:7JK) Headlines

No Headlines